US Stock MarketDetailed Quotes

VRDN Viridian Therapeutics

Watchlist
  • 19.620
  • -0.170-0.86%
Close Nov 21 16:00 ET
  • 19.620
  • 0.0000.00%
Post 16:20 ET
1.55BMarket Cap-4541P/E (TTM)

About Viridian Therapeutics Company

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Company Profile

SymbolVRDN
Company NameViridian Therapeutics
Listing DateJun 18, 2014
Issue Price10.00
Founded2006
CEOMr. Stephen Mahoney
MarketNASDAQ
Employees94
Fiscal Year Ends12-31
Address221 Crescent Street,Suite 401
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02453
Phone1-617-272-4600
Websitehttp://www.viridiantherapeutics.com

Company Executives

  • Name
  • Position
  • Salary
  • Stephen Mahoney
  • President, Chief Executive Officer and Director
  • 12.48M
  • Thomas W. Beetham
  • Chief Operating Officer
  • 4.76M
  • Dr. Thomas Ciulla
  • Chief Medical Officer
  • --
  • Jennifer Tousignant
  • Chief Legal Officer
  • --
  • Seth Harmon
  • Senior Vice President, Finance and Accounting, Principal Accounting Officer and Principal Financial Officer
  • 6.55M
  • Tomas Kiselak
  • Chairman of the Board
  • 503.83K
  • Jennifer K. Moses
  • Independent Director
  • 467.83K
  • Arlene M. Morris
  • Independent Director
  • 477.83K
  • Dr. Sarah Gheuens
  • Independent Director
  • 482.53K
  • Peter Harwin
  • Independent Director
  • 471.83K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data